Definition
PMS describes a pattern of physical and emotional symptoms that start in the luteal phase (after ovulation) and get better within a few days of the period starting. Symptoms range from mild annoyance to severe disruption of daily life. A much less common and more severe form is PMDD (premenstrual dysphoric disorder).
How common is it? (quick regional comparison)
Numbers vary because studies use different definitions and populations. Below are broad, commonly reported estimates.
| Region | Typical estimates |
| United Kingdom (NICE / RCOG) | ~20–40% of women report premenstrual symptoms; 2–4% have severe PMS that prevents normal activities. |
| United States (ACOG / surveys) | Up to 20–30% meet criteria for clinically significant PMS; many more report at least one symptom. |
| Europe | Population studies commonly report ~20–40%, depending on country and methods. |
| Asia & Africa | Reported prevalence varies widely (from lower reported rates to very high in some studies — ~30–70% in certain community samples); heterogeneity and under-reporting are common. Global meta-analyses show large regional differences. |
| PMDD (severe form) | Global reviews estimate ~1–3% (confirmed cases ≈1.6% in some recent analyses). |
Causes of PMS:
The exact cause of PMS is not fully understood, but it is thought to result from a combination of factors, primarily hormonal and neurochemical changes.
- Hormonal Fluctuations
- What it means: Changes in estrogen and progesterone levels during the menstrual cycle, particularly in the luteal phase, are thought to trigger PMS symptoms. These hormones can affect mood, energy, and physical sensations.
- Source: RCOG (Green-top Guideline No. 48) and NICE emphasize cyclical hormonal changes as a primary driver. ACOG notes that sensitivity to these normal fluctuations varies between women. ESHRE and TOG support this, highlighting progesterone’s role in the luteal phase.
- Neurotransmitter Imbalance (Serotonin)
- What it means: Low levels or altered sensitivity to serotonin, a brain chemical that regulates mood, may contribute to emotional symptoms like irritability or depression in PMS.
- Source: NICE and ACOG identify serotonin dysregulation as a key factor in premenstrual dysphoric disorder (PMDD, a severe form of PMS) and milder PMS. RCOG mentions neurotransmitter changes as a contributor. ESHRE and TOG note serotonin’s role in mood-related symptoms.
- Genetic Factors
- What it means: A family history of PMS or PMDD suggests that genes may make some women more sensitive to hormonal or neurotransmitter changes.
- Source: ACOG and ESHRE suggest a genetic predisposition, with some evidence of heritability. RCOG and NICE note that genetic factors may increase susceptibility, though specific genes are not well-defined. TOG mentions familial patterns in severe cases.
- Lifestyle and Environmental Factors
- What it means: Stress, poor diet, lack of exercise, or inadequate sleep can worsen PMS symptoms, though they are not direct causes.
- Source: NICE and RCOG highlight lifestyle factors like stress or obesity as aggravators of PMS. ACOG notes that environmental stressors may amplify symptoms. ESHRE and TOG mention lifestyle as a contributing factor but not a primary cause.
- Individual Sensitivity
- What it means: Some women are more sensitive to normal hormonal changes, possibly due to differences in brain chemistry or hormone receptors, leading to more severe PMS symptoms.
- Source: RCOG, NICE, and ACOG emphasize that individual variation in sensitivity to hormonal fluctuations is a key factor. ESHRE notes this in the context of PMDD. TOG discusses heightened sensitivity in some women.
- Progesterone Metabolism Abnormalities
- What it means: The way the body processes progesterone or its byproducts (e.g., allopregnanolone) may affect mood and physical symptoms in PMS.
- Source: RCOG and ESHRE highlight altered progesterone metabolism as a potential contributor. ACOG notes this in relation to PMDD. NICE and TOG mention it as a less-established factor.
Key Points
- Multifactorial: PMS likely results from a combination of hormonal, neurochemical, and genetic factors, with individual sensitivity playing a major role (RCOG, NICE).
- Not Fully Understood: The precise mechanisms are unclear, and more research is needed (ACOG, ESHRE).
- Risk Factors: Family history, stress, or high sensitivity to hormonal changes increase the likelihood of PMS (TOG, NICE).
Typical symptoms (what people notice)
Common physical: bloating, breast tenderness, headaches, pain, changes in appetite, fatigue.
Common emotional/behavioural: irritability, mood swings, tearfulness, anxiety, poor concentration.
Symptoms follow a monthly pattern and resolve near the period start.
Long-term consequences (if severe and untreated)
• Repeated monthly disruption to work, study and relationships.
• Increased risk of anxiety and depression in some people.
• In PMDD, higher rates of suicidal thoughts and severe functional impairment (rare but serious).
• Reduced quality of life and social participation.
Investigations (what clinicians do)
1. Detailed symptom history (timing, pattern, impact) — ask patients to keep daily symptom ratings across ≥2 cycles (prospective charting) to confirm diagnosis.
2. Exclude other causes: thyroid disease, mood disorders, substance use, medication effects, or physical conditions.
3. Physical exam and targeted blood tests only if history suggests alternate diagnosis.
4. Consider psychiatric review for severe mood symptoms or suicidal ideation.
Treatment options
First step — education & self-help
• Track cycles and symptoms; lifestyle (regular sleep, exercise, limit alcohol/caffeine, balanced diet).
• Stress management, CBT (cognitive behavioural therapy) helps mood symptoms.
Medical treatments
• First-line for many: combined oral contraceptive pill (continuous use reduces cyclical symptoms) or selective serotonin reuptake inhibitors (SSRIs) — effective for mood symptoms (SSRIs can be taken continuously or only in luteal phase).
• Other options: GnRH agonists (for refractory cases, with add-back therapy), spironolactone for physical symptoms, and symptomatic pain relief.
• PMDD often responds well to SSRIs and/or combined hormonal contraception; severe refractory cases may need specialist care.
When to refer
• If symptoms are severe (stop normal activity), if diagnosis uncertain, if there is suicidal ideation, or if first-line measures fail — refer to gynaecology or mental-health services.
Key practical points
• Confirm diagnosis with prospective symptom charting over ≥2 cycles.
• Many women improve with lifestyle changes, CBT or medication.
• PMDD is uncommon but serious — needs prompt assessment and effective treatment
Remember, ALWAYS consult with your GP and/or your gynecologist for your specific treatment options. Every woman is different!
Leave a Reply